RC288 for solid tumors: a Phase 1/2 safety and effectiveness study
Part of Cancer clinical trials.
This study tests a new drug called RC288 to treat solid tumors (cancers that form lumps). Researchers want to see if it's safe and how well it works for people whose cancer hasn't responded to other treatments or has returned.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- Your overall health and ability to do daily activities are good (ECOG score 0–1)
- You are expected to live at least 12 weeks
- You have at least one measurable tumor visible on imaging scans
- Your bone marrow, liver, kidney, and blood clotting function are adequate
- Any side effects from previous cancer treatments have largely recovered
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called RC278 for people with solid tumors that have not spread to the brain. It aims to see if the drug is safe and effective, and may be an option for those who are otherwise fairly healthy.
This trial tests a new drug called RC148, both alone and combined with other treatments, for people with advanced solid tumors that haven't responded to standard therapy. It includes several groups for specific cancers (like non-small cell lung, cervical, stomach, and ovarian cancer) to see if RC148 can shrink tumors or slow their growth.
This trial tests a new drug called HRS-4508 for people with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe, how the body processes it, and if it helps shrink tumors.
This trial tests an experimental drug for people with advanced solid tumors, including small cell lung cancer, that have stopped responding to standard treatments. The goal is to find out if the drug is safe and effective.
This trial tests an experimental drug called HRS-3802 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how the body processes it.
This early-stage study tests a new drug called MK-4884 in patients with advanced cancers that have spread. The trial includes colorectal, kidney, lung, and bile duct cancers, and aims to find the right dose and see if the drug helps shrink tumors.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.